Precision cancer medicine - still expedient for the few
Tidsskr Nor Laegeforen. 2021 Mar 22;141(5).
doi: 10.4045/tidsskr.20.0980.
Print 2021 Mar 23.
[Article in
English,
Norwegian]
No abstract available
Plain language summary
Cancer genome sequencing with the aid of next-generation sequencing is now being introduced as part of routine diagnostics. It allows for off-label treatment of patients with advanced cancer. Unfortunately, this strategy is often to no avail.
MeSH terms
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Neoplasms* / therapy
-
Precision Medicine*